Proteomic Aging Clocks Track Biological Age Reversal in Rentosertib Trial

Researchers from Insilico Medicine and an international group of academic collaborators have applied six independently developed proteomic aging clocks to blood samples from a Phase IIa trial of the AI-designed drug rentosertib, finding that all six models consistently predicted lower biological age in treated patients. The study, published September 7, 2026 in Nature Biotechnology, is the first head-to-head clinical comparison of multiple proteomic aging clocks in a drug intervention…

This article has been indexed from Unite.AI

Read the original article: